{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Perlis RH"],"funding":["NIMH NIH HHS"],"pagination":["2810-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10034848"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(12)"],"pubmed_abstract":["Recent rodent models of antidepressant response implicate a novel set of genes in mechanisms of antidepressant action. The authors examined variants in four such genes (KCNK2 (TREK1), SLC18A2 (VMAT2), S100A10, and HDAC5) for association with remission in a large effectiveness trial of antidepressant treatments. Subjects were drawn from the Sequenced Treatment Alternatives to Relieve Depression (STAR(*)D) study, a multicenter, prospective, effectiveness trial in major depressive disorder (MDD). Outpatients with nonpsychotic MDD were initially treated with citalopram for up to 14 weeks; those who did not remit with citalopram were sequentially randomized to a series of next-step treatments, each for up to 12 weeks. Single-nucleotide polymorphisms in four genes were examined for association w"],"journal":["Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"],"pubmed_title":["Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study."],"pmcid":["PMC10034848"],"funding_grant_id":["N01 MH090003","K23 MH067060"],"pubmed_authors":["Fava M","Trivedi MH","Fagerness J","Purcell S","Perlis RH","Rush AJ","Smoller JW","Moorjani P"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.","description":"Recent rodent models of antidepressant response implicate a novel set of genes in mechanisms of antidepressant action. The authors examined variants in four such genes (KCNK2 (TREK1), SLC18A2 (VMAT2), S100A10, and HDAC5) for association with remission in a large effectiveness trial of antidepressant treatments. Subjects were drawn from the Sequenced Treatment Alternatives to Relieve Depression (STAR(*)D) study, a multicenter, prospective, effectiveness trial in major depressive disorder (MDD). Outpatients with nonpsychotic MDD were initially treated with citalopram for up to 14 weeks; those who did not remit with citalopram were sequentially randomized to a series of next-step treatments, each for up to 12 weeks. Single-nucleotide polymorphisms in four genes were examined for association w","dates":{"release":"2008-01-01T00:00:00Z","publication":"2008 Nov","modification":"2026-05-29T07:52:12.091Z","creation":"2025-07-24T03:03:58.325Z"},"accession":"S-EPMC10034848","cross_references":{"pubmed":["18288090"],"doi":["10.1038/npp.2008.6"]}}